The acquired portfolio includes Nicotinell, also known as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada.

BusinessWire India New Delhi [India] October 4 The Conclave on Advancing Oral Health in India - The Oral Health Collaborative ...

Another notable valuation metric for HLN is its P/B ratio of 2.28. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

EQUITY capital market bankers are rushing to finalise a fresh slate of deals in Europe, before the US presidential election ...

This summary covers recent developments in health news, from Humana's slumping Medicare plan enrollments impacting future ...

In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

Pharmaceutical giant Pfizer Inc. announced on Tuesday that it has reduced its stake in British consumer healthcare company ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual ...

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.